Table 4.2.
Antitumor activity of PM-8 and PM-17 against CO-4 human colon cancer by using SRC assay for i.p. administration of compounds
| Compound | Dose (mg/kg−1) | Administration schedule (i.p.) | Ratio of body weight change (day 6/day 0) | Antitumor activity (T/C, % on day 7) |
|---|---|---|---|---|
| Control | 1.03 ± 0.01 | |||
| PM-8 | 200 | Days 1–5 | 1.07 ± 0.01 | 62.2**a |
| 100 | Days 1–5 | 1.03 ± 0.02 | 67.6*** | |
| 50 | Days 1–5 | 1.03 ± 0.01 | 45.6** | |
| PM-17 | 25 | Days 1–5 | 0.70 ± 0.05 | 42.4** |
| Na5[IMo6O24] · 34H2O | 100 | Days 1–5 | 1.03 ± 0.01 | 70.3*** |
| 5-FU | 30 | Days 1–4 | 0.99 ± 0.01 | 56.0**** |
| ACNU | 10 | Days 1–4 | 0.94 ± 0.08 | 62.4**** |
| CDDP | 2 | Days 1–4 | 0.97 ± 0.02 | 54.4**** |
aSignificantly different from corresponding tumor control group (*p < 0.05; **p < 0.02; ***p < 0.01; ****p < 0.001)